Back to Search
Start Over
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
- Source :
- British Journal of Haematology
- Publication Year :
- 2019
-
Abstract
- Summary This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30 years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease‐free survival (DFS) was 91%. We demonstrate that a risk‐stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy.
- Subjects :
- Adult
Male
Pediatrics
medicine.medical_specialty
paediatric
Adolescent
Short Report
Disease-Free Survival
03 medical and health sciences
Young Adult
0302 clinical medicine
Quality of life
Short Reports
Risk Factors
Antineoplastic Combined Chemotherapy Protocols
Classical Hodgkin lymphoma
Medicine
Humans
Young adult
business.industry
Incidence (epidemiology)
Complete remission
Combined modality treatment
Haematological Malignancy ‐ Clinical
Hematology
Hodgkin Disease
Clinical trial
Survival Rate
030220 oncology & carcinogenesis
Quality of Life
Hodgkin lymphoma
Female
neuropathy
business
030215 immunology
Subjects
Details
- ISSN :
- 13652141
- Volume :
- 189
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- British journal of haematology
- Accession number :
- edsair.doi.dedup.....481f352379ad53f7ed5801f8f230eba1